跳至主要内容
临床试验/NCT04238871
NCT04238871终止不适用

Idiopathic Interstitial Pneumopathy : Genetic and Environmental Determinants From Infancy to Elderly

Institut National de la Santé Et de la Recherche Médicale, France4 个研究点 分布在 1 个国家目标入组 1,600 人开始时间: 2017年6月21日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
1,600
试验地点
4
主要终点
The phenotypic description idiopathic lung disease

研究概览

简要总结

The main objective is to describe the phenotypic features of the paediatric and adult patients with Idiopathic Interstitial Pneumopathy/Pneumopathy Interstitial Diffuse (IIP/PID), at diagnosis and during the follow-up. These data will be critical for the description of the natural history of the various forms of IIP/PID.

详细描述

The French RaDiCo-PID : Idiopathic Interstitial Pneumopathy registry is an ongoing observational prospective and retrospective cohort with longitudinal long-term follow-up includes pediatric and adult patients with Idiopathic Interstitial Lung Disease (ILD) from the reference and competence centers.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

性别
All
接受健康志愿者

入选标准

  • Clinical criteria: chronic respiratory insufficiency manifestations including dyspnea/tachypnea, cough, and cyanosis during exercise or at rest
  • Radiological criteria: characteristic chest High-Resolution Computed Tomography (HRCT) abnormalities including widespread ground glass or alveolar attenuation, reticulation often associated with traction bronchiectasis, and honeycombing
  • Functional criteria: pulmonary function test abnormalities reflecting a restrictive pattern and including: loss of lung volume, vital capacity (VC), total lung capacity (TLC); reduction in the diffusion capacity of the lung for carbon monoxide (DLCO), gas exchange abnormalities, and altered ventilatory response to exercise
  • Patients (parents/guardians for paediatric/patients) having given an informed consent to participate in the protocol
  • Patients affiliated to the "Regime National d'Assurance Maladie"

排除标准

  • Patients with diffuse parenchymal lung diseases caused by drug toxicity, immunodeficiency, proliferative disorders including histiocytosis, and metabolic disorders
  • Patients (parents/guardians for paediatric patient) not able to approve/understand the protocol

研究组 & 干预措施

children or adults with Idiopathic Lung Disease

结局指标

主要结局

The phenotypic description idiopathic lung disease

时间窗: Up to 10 years

Phenotypic description will be measure demographic data, environmental data, socio-professionnal data, medical history, comorbidities, clinical examination, biological assessment (hematology; biochemistry; hemostasis...), pulmonary biopsy, bronchial-pulmonary imaging; symptom description; respiratory function (arterial blood gas, pulmonary fonction testing, six minute-walk testing, cardiopulmonary exercise testing, polysomnography), treatments, quality of life questionnaire (SF36 and SF10)

次要结局

  • Identify gene factors involved in disease initiation and progression(Up to 10 years)
  • Investigate the extent to which environmental and co-morbidity factors may influence disease severity and outcome(Up to 10 years)
  • Identify and validate biomarkers for disease diagnosis and progression(Up to 10 years)

研究者

发起方
Institut National de la Santé Et de la Recherche Médicale, France
申办方类型
Other Gov
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

RaDiCo PID Cohort (RaDiCo-ILD Cohort in English) | 临床试验